NYSE:IBIO iBio (IBIO) Stock Price, News & Analysis $0.85 +0.00 (+0.47%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About iBio Stock (NYSE:IBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iBio alerts:Sign Up Key Stats Today's Range$0.83▼$0.8850-Day Range$0.70▼$6.4152-Week Range$0.64▼$6.89Volume234,779 shsAverage Volume402,149 shsMarket Capitalization$8.43 millionP/E RatioN/ADividend YieldN/APrice Target$4.30Consensus RatingBuy Company OverviewiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More… iBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreIBIO MarketRank™: iBio scored higher than 35% of companies evaluated by MarketBeat, and ranked 698th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiBio has only been the subject of 1 research reports in the past 90 days.Read more about iBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iBio are expected to decrease in the coming year, from ($1.74) to ($2.05) per share.Price to Book Value per Share RatioiBio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IBIO. News and Social Media2.8 / 5News Sentiment0.06 News SentimentiBio has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for iBio this week, compared to 0 articles on an average week.Search Interest11 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows1 people have added iBio to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.58% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesiBio (NYSE:IBIO) Given Buy Rating at Chardan CapitalMay 6 at 2:33 AM | americanbankingnews.comiBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5 at 10:26 AM | finance.yahoo.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 7, 2025 | Golden Portfolio (Ad)iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5 at 8:00 AM | globenewswire.comiBio Reports Fiscal Third Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comiBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement TransactionMay 1, 2025 | finanznachrichten.deiBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross ProceedsApril 29, 2025 | quiverquant.comiBio Raises $6.2 Million Through Warrant Inducement TransactionApril 29, 2025 | globenewswire.comSee More Headlines IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $2.45 at the start of the year. Since then, IBIO stock has decreased by 65.1% and is now trading at $0.8540. View the best growth stocks for 2025 here. How were iBio's earnings last quarter? iBio, Inc. (NYSE:IBIO) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.46). Who are iBio's major shareholders? Top institutional shareholders of iBio include Iridian Asset Management LLC CT (0.59%). View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Fastly (FSLY), Fortinet (FTNT), Snowflake (SNOW), Tesla (TSLA), Arbor Realty Trust (ABR) and Accenture (ACN). Company Calendar Last Earnings11/12/2024Today5/06/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:IBIO Previous SymbolNYSE:IBIO CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$4.30 High Stock Price Target$5.00 Low Stock Price Target$3.60 Potential Upside/Downside+405.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,910,000.00 Net MarginsN/A Pretax Margin-3,795.73% Return on Equity-73.15% Return on Assets-45.51% Debt Debt-to-Equity Ratio0.05 Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual Sales$375,000.00 Price / Sales22.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book0.60Miscellaneous Outstanding Shares9,875,000Free Float9,818,000Market Cap$8.39 million OptionableN/A Beta1.19 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:IBIO) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.